Analytical Data
-
基因名
Uteroglobin/SCGB1A1
- Application
-
别名
Clara cell phospholipid-binding protein, Clara cells 10 kDa secretory protein, CC10, Secretoglobin family 1A member 1, Urinary protein 1
-
种属
Human
-
表达系统
E. coli
-
标签
Tag Free
-
纯度
Greater than 95% as determined by SDS-PAGE.
-
蛋白编号
P11684
-
表达区间
22-91aa
-
分子量
7.9 kDa
-
内毒素
< 1.0 EU per μg protein as determined by the LAL method.
-
性状
Freeze-dried powder
-
缓冲液
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
复溶方法
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- 个性化定制
-
稳定性测试
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
保存条件 & 期限
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
运输条件
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Uteroglobin, also known as secretoglobin 1A1 (SCGB1A1), is a small secreted protein primarily expressed in the epithelial cells of the uterus, lungs, and various tissues. It plays a critical role in reproductive functions, immune response, and inflammation regulation. Research has highlighted its involvement in various physiological and pathological processes, including pregnancy, fibrosis, and respiratory diseases. Uteroglobin exhibits anti-inflammatory properties and has shown potential as a biomarker for certain diseases, making it a compelling target for therapeutic intervention. Its ability to bind and modulate the activity of inflammatory mediators places it at the forefront of studies aimed at developing treatments for conditions like asthma and chronic obstructive pulmonary disease (COPD). Significant efforts have been directed towards producing recombinant Uteroglobin/SCGB1A1 for both research and therapeutic applications. By utilizing recombinant DNA technology, researchers aim to produce this protein in sufficient quantities for detailed functional studies and potential clinical applications. Understanding the structure-function relationship of Uteroglobin is also a crucial aspect of ongoing research, as it will inform the development of novel drugs that leverage its inherent properties. Overall, the study of Uteroglobin/SCGB1A1 as a recombinant protein holds promise for advancing knowledge in immunology and therapeutic strategies for inflammatory diseases.
